Federman & Sherwood Announces Investigation Into GeneDx Holdings Corp. (NASDAQ: WGS) on Behalf of Shareholders
May 7, 2026 — The law firm of Federman & Sherwood, a national plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, announced today that it has commenced an independent investigation into potential securities law violations by GeneDx Holdings Corp. (“GeneDx” or the “Company”) (NASDAQ: WGS) on behalf of purchasers of the Company’s common stock.
Details of the Investigation:
Federman & Sherwood’s investigation focuses on whether GeneDx and certain of its officers and directors made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s business operations, financial condition, revenue outlook, and future prospects.
The investigation will examine whether statements issued by the Company concerning expected revenue growth, testing volume trends, collection rates, and 2026 financial guidance were accurate and complete. The investigation also will assess whether GeneDx properly disclosed adverse developments affecting its revenue performance and whether investors were adequately informed of risks impacting the Company’s business outlook.
According to publicly available reports, GeneDx stock declined more than 45% on May 5, 2026 after the Company reported first quarter revenue below analyst expectations and reduced its full-year 2026 revenue guidance. Reports further indicate that, earlier in 2026, GeneDx had reaffirmed its outlook and advised investors that first quarter performance was tracking expectations.
Federman & Sherwood is investigating whether these and other statements may have misled investors and whether corrective disclosures resulted in financial losses for shareholders who purchased or held GeneDx securities during the relevant period.
Background:
GeneDx Holdings Corp. is a genomic testing and diagnostics company focused on genetic testing and data interpretation services. The Company’s common stock is publicly traded, and during the relevant period GeneDx issued statements concerning its operational performance, growth expectations, and financial outlook. Recent developments affecting the Company’s reported results and revised guidance have raised questions regarding the timing and completeness of disclosures made to the investing public.
What This Means for Investors:
Investors who purchased or otherwise acquired GeneDx Holdings Corp. common stock and believe they suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
Contact Information
Phone: 1-800-237-1277 | Email: info@federmanlaw.com